Public procurement notice: Contract Award Notice
Published: 2021-05-03
Buyer: The NHS Commissioning Board (operating under the name of NHS England)
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 162800000 GBP
Award criteria: Lowest price

Technical requirements: National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England
NHS National framework agreement for the supply of aseptically prepared cytotoxic medicines and monoclonal antibodies – North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
ITT lists Purchasing points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.
NHS National framework agreement for the supply of aseptically prepared cytotoxic medicines and monoclonal antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.


Winner: Qualasept Ltd t/a Bath ASU
Award value: 162800000
Number of bids: 1